Leerink Partners Upgrades 2seventy bio to Outperform, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Daina Graybosch has upgraded 2seventy bio (NASDAQ:TSVT) from Market Perform to Outperform and increased the price target from $5 to $18, indicating a positive outlook on the company's performance.
January 31, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
2seventy bio has been upgraded by Leerink Partners from Market Perform to Outperform with a significant raise in price target from $5 to $18, suggesting strong confidence in the company's future performance.
Upgrades by analysts, especially with a substantial increase in price target, typically lead to positive investor sentiment and can drive the stock price up in the short term. The upgrade from Market Perform to Outperform reflects a strong vote of confidence in 2seventy bio's prospects, which is likely to be viewed favorably by the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100